Clinical Trials Browser

Dendritic Cell Sarcoma, Interdigitating × Sarcoma × 90 days × Clear all

NCT07472621 2026-03-16

Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Not yet recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT07249905 2026-03-03

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Phase 1/2 Recruiting

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT07443137 2026-03-02

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Phase 1 Not yet recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT06014762 2026-02-27

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Phase 1 Recruiting

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Phase 2 Suspended

18 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT07121946 2026-02-10

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Phase 1 Recruiting

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT07389356 2026-02-05

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

Phase NA Not yet recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT05563844 2026-02-04

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Phase 2 Active not recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06846463 2026-01-23

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Phase 2 Recruiting

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT07288879 2026-01-08

DALY II Japan

Phase 2 Recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Phase 2 Active not recruiting

22 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT06220032 2026-01-05

HO170DLBCL

Phase 3 Recruiting

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity